Quarterly report [Sections 13 or 15(d)]

Modifications to License Agreements

v3.26.3
Modifications to License Agreements
9 Months Ended
Sep. 30, 2026
Modifications To License Agreements  
Modifications to License Agreements

Note 11 – Modifications to License Agreements

 

Amendment of our License Agreement with Yuhan Corporation

 

On August 14, 2026, Yuhan Corporation executed Amendment No. 2 to our existing license agreement dated August 19, 2020, effective August 14, 2026, which extended to August 14, 2027 the deadline to dose the first patient in a Phase 2B clinical trial, Phase 3 clinical trial or other pivotal clinical trial.

 

Termination of our License Agreement with Elion Oncology, Inc.

 

On July 23, 2026, we terminated our license agreement, dated August 23, 2020 with Elion Oncology, Inc. (“Elion License Agreement”), pursuant to a settlement agreement entered into on that date (the “Settlement Agreement”). Pursuant to the Settlement Agreement, the parties agreed to settle all claims in respect of our litigation regarding the Elion License Agreement and to terminate the Elion License Agreement without further obligation of either party, with us returning the PCS6422 program to Elion. In connection with the Settlement Agreement, the parties exchanged mutual releases of all claims relating to the Elion License Agreement, the PCS6422 program and the related litigation. As part of the Settlement Agreement, we agreed to pay Elion the sum of $0.7 million. In addition, we agreed to grant to Elion a non-voting equity interest equal to 7.5% of the fully diluted pre-money equity capitalization of any newly formed entity whose assets include one or more of PCS499, PCS12852, or PCS11T, if the formation or spin-out is completed within one year following the effective date of the Settlement Agreement. On August 7, 2026, the filed stipulation became effective as a final dismissal with prejudice.

 

Accordingly, we are terminating the Phase 2 trial of PCS6422 in advanced/metastatic breast cancer.